Milan, Italy, March 17 to 19, 2025 – CIS BIOPHARMA, a Basel-based leader in Oncology, was participating at the Annual BIO-Europe Spring, a premier partnering conference for the global life sciences industry in Milan, Italy.

CIS BIOPHARMA was showcasing its pipeline during the conference, highlighting L1CAM being the new emerging target in SCLC and NETs. Our innovative approach aims to become standard-of-care, leveraging our expertise in bioconjugates to advance our lead candidate to the clinic.

«BIO-Europe Spring offers an unparalleled opportunity to connect with decision-makers and explore emerging trends and partnerships in life sciences,» says Dominik Brücher, CTO. «We look forward to continuing our conversations with financial and strategic partners, observing a good traction for our approach across the board.»

About CIS BIOPHARMA AG

CIS BIOPHARMA is a privately owned, Basel-based oncology company that develops next-generation immuno-conjugates to address aggressive forms of tumors. The product pipeline includes antibody-drug conjugates, ADCs, and radioligand therapies, RLTs, selectively targeting tumor cells. CIS BIOPHARMA aims to help cancer patients live longer and better lives.